| Year |
Title |
Altmetric |
| 2021
|
First-In-Human, First-In-Class, Phase I Trial of the Fucosylation Inhibitor SGN-2FF in Patients with Advanced Solid Tumors
2021
|
|
| 2021
|
Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study.
Lung Cancer.
161:180-188.
2021
|
|
| 2021
|
SWOG S1400A (NCT02154490): A Phase II Study of Durvalumab for Patients With Previously Treated Stage IV or Recurrent Squamous Cell Lung Cancer (Lung-MAP Sub-study).
Clinical Lung Cancer.
22:178-186.
2021
|
|
| 2021
|
Overall survival of patients with triple-class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH.
American Journal of Hematology.
96:E5-E8.
2021
|
|
| 2020
|
First-In-Human Phase 1 Clinical Trials – A Single-Center Experience In The Era Of Modern Oncotherapeutics.
Scientific Reports.
10.
2020
|
|
| 2019
|
Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors.
Cancer Chemotherapy and Pharmacology.
83:551-559.
2019
|
|
| 2019
|
Lung cancer in nonelderly patients: Facility and patient characteristics associated with not receiving treatment.
Journal of the National Comprehensive Cancer Network : JNCCN.
17:931-939.
2019
|
|
| 2017
|
Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score.
Journal of Thrombosis and Haemostasis.
15:2184-2187.
2017
|
|
| 2017
|
A pilot study of zoledronic acid in the treatment of patients with advanced malignant pleural mesothelioma.
Lung Cancer: Targets and Therapy.
8:39-44.
2017
|
|
| 2017
|
Pilot phase II study of metronomic chemotherapy in combination with bevacizumab in patients with advanced non-squamous non-small cell lung cancer.
Lung Cancer.
106:125-130.
2017
|
|
| 2017
|
Phase I Results from a Study of Crizotinib in Combination with Erlotinib in Patients with Advanced Nonsquamous Non–Small Cell Lung Cancer.
Journal of Thoracic Oncology.
12:145-151.
2017
|
|
| 2017
|
Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study
2017
|
|
| 2016
|
ORAL02.01: Safety and Efficacy of Single-Agent Rovalpituzumab Tesirine, a DLL3-Targeted ADC, in Recurrent or Refractory SCLC: Topic: Medical Oncology..
Journal of Thoracic Oncology.
11:S252-S253.
2016
|
|
| 2016
|
Phase II study of a novel taxane (Cabazitaxel-XRP 6258) in previously treated advanced non-small cell lung cancer (NSCLC) patients.
Cancer Chemotherapy and Pharmacology.
78:509-515.
2016
|
|
| 2015
|
Phase I/IIa study of sequential chemotherapy regimen of bendamustine/irinotecan followed by etoposide/carboplatin in untreated patients with extensive disease small cell lung cancer (EDSCLC).
Cancer Chemotherapy and Pharmacology.
76:949-955.
2015
|
|
| 2014
|
An open-label phase Ib dose-escalation study of TRC105 (anti-endoglin antibody) with bevacizumab in patients with advanced cancer.
Clinical Cancer Research.
20:5918-5926.
2014
|
|
| 2014
|
EGFR expression and survival in patients given cetuximab and chemoradiation for stage III non-small cell lung cancer: A secondary analysis of RTOG 0324.
Radiotherapy and Oncology.
112:30-36.
2014
|
|
| 2014
|
Endoglin for targeted cancer treatment topical collection on evolving therapies.
Current Oncology Reports.
16.
2014
|
|
| 2013
|
Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: A phase 3, open-label, randomised trial
2013
|
|
| 2012
|
Leukaemia cutis
2012
|
|
| 2012
|
Sunitinib plus erlotinib for the treatment of advanced/metastatic non-small-cell lung cancer: A lead-in study.
Journal of Thoracic Oncology.
7:1406-1416.
2012
|
|
| 2011
|
Phase II study of cetuximab in combination with chemoradiation in patients with stage IIIA/B non-small-cell lung cancer: RTOG 0324.
Journal of Clinical Oncology.
29:2312-2318.
2011
|
|
| 2011
|
Phase II study of dose-intense chemotherapy with sequential topoisomerase-targeting regimens with irinotecan/oxaliplatin followed by etoposide/carboplatin in chemotherapy naive patients with extensive small cell lung cancer.
Lung Cancer.
72:219-223.
2011
|
|
| 2010
|
Sunitinib in combination with docetaxel in patients with advanced solid tumors: A phase I dose-escalation study.
Cancer Chemotherapy and Pharmacology.
66:669-680.
2010
|
|
| 2010
|
The potential benefits of low-molecular-weight heparins in cancer patients.
Journal of Hematology and Oncology.
3.
2010
|
|
| 2010
|
A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV non-small cell lung cancer.
Cancer Chemotherapy and Pharmacology.
65:227-234.
2010
|
|
| 2009
|
Vorinostat in solid and hematologic malignancies.
Journal of Hematology and Oncology.
2.
2009
|
|
| 2009
|
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma.
Modern Pathology.
22:1032-1043.
2009
|
|
| 2009
|
A phase I trial of sns-314, a novel and selective pan-aurora kinase inhibitor, in advanced solid tumor patients..
Journal of Clinical Oncology.
27:2536.
2009
|
|
| 2009
|
Intensive anti-inflammatory therapy with dexamethasone in patients with non-small cell lung cancer: Effect on chemotherapy toxicity and efficacy.
Cancer Chemotherapy and Pharmacology.
63:731-743.
2009
|
|
| 2008
|
Non-small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:228-269.
2008
|
|
| 2008
|
Small cell lung cancer.
Journal of the National Comprehensive Cancer Network : JNCCN.
6:294-314.
2008
|
|
| 2007
|
A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer Scheduled to Receive First-Line Chemotherapy.
Journal of Thoracic Oncology.
2:210-220.
2007
|
|
| 2006
|
Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
Journal of Clinical Oncology.
24:5025-5033.
2006
|
|
| 2006
|
Non-small cell lung cancer: Clinical Practice Guidelines in Oncology™.
Journal of the National Comprehensive Cancer Network : JNCCN.
4:548-582.
2006
|
|
| 2006
|
Small cell lung cancer: Clinical Practice Guidelines in Oncology™.
Journal of the National Comprehensive Cancer Network : JNCCN.
4:602-622.
2006
|
|
| 2006
|
Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.
Chest.
130:1796-1802.
2006
|
|
| 2005
|
Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naïve advanced non-small-cell lung cancer.
Journal of Clinical Oncology.
23:9089-9096.
2005
|
|
| 2005
|
Phase I study of90Y-CC49 monoclonal antibody therapy in patients with advanced non-small cell lung cancer: Effect of chelating agents and paclitaxel co-administration.
Cancer Biotherapy and Radiopharmaceuticals.
20:467-478.
2005
|
|
| 2005
|
Phase I/IIa study of cisplatin and gemcitabine as induction chemotherapy followed by concurrent chemoradiotherapy with gemcitabine and paclitaxel for locally advanced non-small-cell lung cancer.
Journal of Clinical Oncology.
23:6664-6673.
2005
|
|
| 2005
|
Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.
Annals of Oncology.
16:1069-1075.
2005
|
|
| 2004
|
Individualized patient dosing in phase I clinical trials: The role of Escalation with Overdose Control in PNU-214936.
Journal of Clinical Oncology.
22:602-609.
2004
|
|
| 2003
|
Phase II study of docetaxel plus enoxaparin in chemotherapy-naive patients with metastatic non-small cell lung cancer: Preliminary results.
Lung Cancer.
42:237-245.
2003
|
|
| 2003
|
Chemotherapy tolerance after radioimmunotherapy with 90Y-CC49 monoclonal antibody in patients with advanced non-small cell lung cancer: Clinical effects and hematologic toxicity.
Cancer Biotherapy and Radiopharmaceuticals.
18:317-325.
2003
|
|
| 2003
|
Comparison of biodistribution, dosimetry, and outcome from clinical trials of radionuclide-CC49 antibody therapy.
Cancer Biotherapy and Radiopharmaceuticals.
18:393-404.
2003
|
|
| 2002
|
Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting 90Y-antibody therapy.
Journal of Nuclear Medicine.
43:1245-1253.
2002
|
|
| 2002
|
Concurrent chemoradiation therapy with cisplatin and paclitaxel for locally advanced non-small cell lung cancer: Long-term follow-up of a phase I trial.
Lung Cancer.
37:189-199.
2002
|
|
| 2001
|
Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer.
Journal of Clinical Oncology.
19:3234-3243.
2001
|
|
| 2000
|
A phase I study of combined UFT plus leucovorin and radiotherapy for pancreatic cancer
2000
|
|
| 1999
|
Monoclonal antibodies as potentiators of radiotherapy and chemotherapy in the management of head and neck cancer.
Current Opinion in Oncology.
11:187-190.
1999
|
|
| 1999
|
Phase I/IIa study of concurrent paclitaxel and cisplatin with radiation therapy m locally advanced non-small cell lung cancer: Analysis of early and late pulmonary morbidity.
Seminars in Radiation Oncology.
9:136-147.
1999
|
|
| 1997
|
A Phase II study of topotecan in patients with recurrent head and neck cancer: Identification of an active new agent
1997
|
|
| 1997
|
Granulocyte-colony stimulating factor (filgrastim) accelerates granulocyte recovery after intensive postremission chemotherapy for acute myeloid leukemia with aziridinyl benzoquinone and mitoxantrone: Cancer and leukemia group B study 9022.
Blood.
89:780-788.
1997
|
|
| 1996
|
Prolonged infusion of etoposide in patients with advanced non-small cell lung cancer
1996
|
|
| 1996
|
Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Cancer Chemotherapy and Pharmacology.
38:459-465.
1996
|
|
| 1994
|
Phase 2 study of prolonged administration of oral etoposide in combination with weekly cisplatin in advanced non-small cell lung cancer
1994
|
|
| 1993
|
Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer.
Investigational New Drugs.
11:61-65.
1993
|
|
| 1993
|
Hemostatic abnormalities associated with monoclonal gammopathies.
American Journal of the Medical Sciences.
306:359-366.
1993
|
|
| 1992
|
A phase II trial of CI-921 in advanced malignancies.
Investigational New Drugs.
10:309-312.
1992
|
|
| 1992
|
Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck.
Cancer Chemotherapy and Pharmacology.
31:167-169.
1992
|
|
| 1988
|
Lupus anticoagulant and Waldenstrom's macroglobulinemia..
Boletin de la Asociacion Medica de Puerto Rico.
80:408-412.
1988
|
|
| 1988
|
Effect of mopidamol on survival in carcinoma of the lung and colon: Final report of veterans administration cooperative study no. 188
1988
|
|
| 1988
|
Trimetrexate as a single agent in patients with advanced head and neck cancer.
Seminars in Oncology.
15:22-26.
1988
|
|
| 1988
|
Trimetrexate combined with cisplatin or etoposide in the treatment of nonsmall cell lung cancer: A pilot study.
Seminars in Oncology.
15:38-40.
1988
|
|
| 1985
|
Phase II trial of diaziquone in patients with colon cancer
1985
|
|
| 1984
|
Randomized phase III comparison of three doxorubicin-based chemotherapy regimens in advanced non-small cell lung cancer: A Southeastern Cancer Study Group trial.
Journal of Clinical Oncology.
2:391-395.
1984
|
|
| 1981
|
Radionuclide angiography: Superior vena caval obstruction.
Seminars in Nuclear Medicine.
11:325-326.
1981
|
|
| 1981
|
Randomized comparison of cyclophosphamide (C), adriamycin (A), methotrexate (M) and folinic acid (F) vs cyclophosphamide, adriamycin and cis-platinum (P) vs cyclophosphamide and adriamycin in advanced non small cell lung cancer (NSCLC)
1981
|
|
| 1980
|
Hairy cell leukemia. Case report and review of the literature..
Boletin de la Asociacion Medica de Puerto Rico.
72:566-573.
1980
|
|
| 1980
|
Combination chemotherapy with cyclophosphamide, adriamycin, intermediate dose methotrexate, and folinic acid rescue (CAMF) in advanced lung cancer.
Cancer.
45:1-5.
1980
|
|
| 1979
|
Serum concentration of methotrexate (MTX) during high, intermediate and low dosage schedules
1979
|
|
| 1978
|
Recent advances in the management of aplastic anemia: a clinical review and case report..
Boletin de la Asociacion Medica de Puerto Rico.
70:219-226.
1978
|
|
| 1977
|
Evaluation of cellular mediated immunity in a normal adult population..
Boletin de la Asociacion Medica de Puerto Rico.
69:64-69.
1977
|
|
| 1977
|
Cyclophosphamide, adriamycin, methotrexate + folinic acid rescue (CAMFAR) treatment of metastatic adenocarcinoma of the lung
1977
|
|
| 1977
|
Demonstration of Cryptococcus neoformans in a Stained Bone Marrow Specimen.
JAMA Internal Medicine.
137:688-690.
1977
|
|
| 1977
|
Mucosal eosinophilic gastroenteritis with systemic involvement.
American Journal of Medicine.
62:139-143.
1977
|
|
| 1976
|
Hematologic toxicity from bleomycin in advanced cancer patients..
The Alabama journal of medical sciences.
13:380-383.
1976
|
|
